Pharmaceuticals, Biotechnology and Life Sciences
Novartis’s division Sandoz, and Pear Therapeutics, have launched reSET for patients with Substance Use Disorder (SUD), which is th efirst…
Sandoz said Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has…
Novartis’s Sandoz has secured European Commission’s approval for biosimilar Zessly, the company said Thursday.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion…
Sandoz, a Novartis division and the global leader in biosimilars, today announced a global partnership with Asia’s premier biopharmaceuticals company,…
Novartises division Sandoz has asked the FDA to review their Biologic License Application for biosimilar adalimumad, related to Humira, for…
Novartis division Sandoz has gotten acceptance for its biosimilar to Amgen’s Neulasta by the European Medicines Agency (EMA) for regulatory…
Sandoz, a Novartis division has reported new data on its proposed biosimilar adalimumab.
Rituxan is used to treat blood cancers including non-Hodgkin’s lymphoma (follicular lymphoma and diffuse large B-cell lymphoma) and chronic lymphocytic leukemia, as well as immunological diseases such as rheumatoid arthritis.
Novartis ahs won European clerance for Erelzi, as the European Commission approved it for Novartis’s division Sandoz.